- Professor, Department of Neurology
Co-director, Comprehensive MS Center
Director, Lourie Center for Pediatric MS
Director, SBU Neuropsychology Research
LAUREN KRUPP MD
- AFFINITY HEALTH PLAN
- AGEWELL (FIDA)
- BEECH STREET
- CIGNA GREAT WEST HEALTHCARE
- CIGNA HMO
- CIGNA PPO
- EMBLEM GHI CBP
- EMBLEM HIP-HMO
- EMBLEM HIP-MEDICAID
- EMBLEM HIP-MEDICARE
- EMPIRE BLUE CHOICE HMO
- EMPIRE BLUE CHOICE INDEMNITY PLANS
- EMPIRE BLUE CHOICE PPO
- EMPIRE BLUE CHOICE SENIOR PLAN
- FIDELIS CARE NEW YORK
- ISLAND GROUP ADMINISTRATION
- MAGNACARE HEALTH REPUBLIC EXCHANGE
- MULTIPLAN PHCS
- MULTIPLAN SAVILITY
- NO FAULT
- UNITED EMPIRE PLAN (NYSHIP)
- UNITED HEALTHCARE
- UNITED OXFORD FREEDOM PLAN
- UNITED OXFORD LIBERTY PLAN
- VISITING NURSE SERVICES (FIDA)
- VYTRA (except SMART START)
- WORKERS COMP
Education & Training
- MD, Albert Einstein College of Medicine, Yeshiva University, NY (1981)
- Neurology, Albert Einstein College of Medicine, NY (1985)
Neuroimmunology, National Institute of Health, Bethesda, MD (1987)
Academic & Other
- Teaching Activity:
- Medical students, residents, fellows
- Year Appointed at
Co-Director MS Comprehensive Care Center, Stony Brook University.
Director Neuropsychology Research, Stony Brook University.
Leadership Award National Multiple Sclerosis Society, 2000.
Health Professional of the Year National Multiple Sclerosis Society, 2002.
Pediatric and Adult Mutilple Sclerosis Research Grants and Clinical Trials.
Investigational Drug Trials:
1. HMR1726 (Teriflunomide)EFC 6260
2. Avonex NPC Biogen
3. Rebif Serono
4. Fingolimod (FTY720) Novartis
1. Study measuring memory, attention, and other cognitive functions, along with mood, stress and fatigue
Internet based study to examine memory, attention and mood
STRATIFY-2: JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving of Considering Treatment with Tysabri SURPASS - 101MS325: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon B-1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis
Mindfulness Based Stress Reduction in MS
A Longitudinal Study of Mild Cognitive Impairment in Patients with MS
Specimen Databank for Patients with Adult Multiple Sclerosis, Pediatric Multiple Sclerosis and Other Neurologic Disorders
- Clinical Practice Began:
179 N. BELLE MEAD ROAD,
1. Krupp LB, Belman AL, Cianciulli C, Milazzo M, Blitz K, Morgan T, Melville P: Clinical, demographic and cognitive features of childhood onset multiple sclerosis. Multiple Sclerosis (in Progress).
2. Christodoulou C, Krupp LB, Melville P, Scherl W, Morgan T, McIlree C: Cognitive screening of MS patients recruited for a clinical trial. Multiple Sclerosis (in press).
3. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B, Kornheiser L: A randomized, double-masked clinical trial studying the treatment of post-Lyme disease. Neurology (suppl) 58:A405
4. Cianciulli C, Krupp L, Belman A, Preston T, Morgan T, Mattis P, Blitz K, Wilson B, Novak G: Neuropsychological profile of children with multiple sclerosis: a pilot study to define areas of impairment and plan cognitive rehabilitation. Ann Neur (suppl)2001:75
More effective diagnostic tools have lead to a greater understanding of pediatric multiple sclerosis (MS), a disease that was, until now, believed to primarily affect adults. Multiple Sclerosis is now known to affect eight to ten thousand children under the age of eighteen, while still another ten to fifteen thousand suffer from what could be symptoms of MS. To help focus efforts to combat this disease, the National MS Society has established a network of Pediatric MS Centers of Excellence throughout the United States. Six such centers have been designated to date.
One of these newly-established centers is here at Stony Brook headed by Dr. Lauren Krupp. Dr. Krupp, professor of Neurology and Co-Director of the MS Comprehensive Care Center at Stony Brook, will serve as project director and will be responsible for successfully leading the center to meet the goals "fighting to end the devastating effects of MS". She will also chair the Steering Committee that will ensure that all six centers work together by collecting standardized data and sharing resources to treat as many children as possible while setting a comprehensive care plan for pediatric MS patients now and in the future. This includes accurate diagnosis, treatment, rehabilitation, psycho-social issues as well as educational components. Additional information about the National Pediatric MS Center at Stony Brook is available at pediatricmscenter.org
Information provided by MSActiveSource.com